Shares of Rosetta Genomics Ltd. (NASDAQ:ROSG) gained a third of their value on Thursday, subsequent Aegis Capital’s initiation coverage with a Buy plus a price target of $16. The stocks had notably spiked on Monday as well, on word of new management hires.
Johnson & Johnson (NYSE:JNJ) division Janssen Biologics said that it has started the Phase 3 development program for sirukumab as part of a collaboration with GlaxoSmithKline (NYSE:GSK). The drug is a human anti-interleukin-6 monoclonal antibody which is being evaluated for the treatment of adults who suffer from moderately to severely active rheumatoid arthritis.
Don’t Miss: Why are Facebook Founders DUMPING Shares?
Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.